Functional polymorphisms of FAS and FASL gene and risk of breast cancer - pilot study of 134 cases.

Fas/Fas ligand (FasL) system is one of the key apoptotic signaling entities in the extrinsic apoptotic pathway. De-regulation of this pathway, i.e. by mutations may prevent the immune system from the removal of newly-formed tumor cells, and thus lead to tumor formation. The present study investigate...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Mohammad Hashemi, Aliakbar Fazaeli, Saeid Ghavami, Ebrahim Eskandari-Nasab, Farshid Arbabi, Mohammad Ali Mashhadi, Mohsen Taheri, Wiem Chaabane, Mayur V Jain, Marek J Łos
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2013
Materias:
R
Q
Acceso en línea:https://doaj.org/article/7e2d543571ef413db0b9f32ac554a79c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:7e2d543571ef413db0b9f32ac554a79c
record_format dspace
spelling oai:doaj.org-article:7e2d543571ef413db0b9f32ac554a79c2021-11-18T08:01:52ZFunctional polymorphisms of FAS and FASL gene and risk of breast cancer - pilot study of 134 cases.1932-620310.1371/journal.pone.0053075https://doaj.org/article/7e2d543571ef413db0b9f32ac554a79c2013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23326385/?tool=EBIhttps://doaj.org/toc/1932-6203Fas/Fas ligand (FasL) system is one of the key apoptotic signaling entities in the extrinsic apoptotic pathway. De-regulation of this pathway, i.e. by mutations may prevent the immune system from the removal of newly-formed tumor cells, and thus lead to tumor formation. The present study investigated the association between -1377 G/A (rs2234767) and -670 A/G (rs1800682) polymorphisms in Fas as well as single nucleotide polymorphisms INV2nt -124 A/G (rs5030772) and -844 C/T (rs763110) in FasL in a sample of Iranian patients with breast cancer. This case-control study was done on 134 breast cancer patients and 152 normal women. Genomic DNA was extracted from whole blood samples. The polymorphisms were determined by using tetra-ARMS-PCR method. There was no significant difference in the genotype distribution of FAS rs2234767 polymorphism between cases and controls. FAS rs1800682, FASL rs5030772, and FASL rs763110 genotypes showed significant associations with an increasing risk of breast cancer (odds ratio OR = 3.18, P = 0.019; OR = 5.08, P = 0.012; OR = 2.40, P = 0.024, respectively). In conclusion, FAS rs2234767 was not associated with breast cancer risk. Though, FAS rs1800682, FASL rs5030772, and FASL rs763110 polymorphisms were associated with the risk of breast cancer in the examined population.Mohammad HashemiAliakbar FazaeliSaeid GhavamiEbrahim Eskandari-NasabFarshid ArbabiMohammad Ali MashhadiMohsen TaheriWiem ChaabaneMayur V JainMarek J ŁosPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 1, p e53075 (2013)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Mohammad Hashemi
Aliakbar Fazaeli
Saeid Ghavami
Ebrahim Eskandari-Nasab
Farshid Arbabi
Mohammad Ali Mashhadi
Mohsen Taheri
Wiem Chaabane
Mayur V Jain
Marek J Łos
Functional polymorphisms of FAS and FASL gene and risk of breast cancer - pilot study of 134 cases.
description Fas/Fas ligand (FasL) system is one of the key apoptotic signaling entities in the extrinsic apoptotic pathway. De-regulation of this pathway, i.e. by mutations may prevent the immune system from the removal of newly-formed tumor cells, and thus lead to tumor formation. The present study investigated the association between -1377 G/A (rs2234767) and -670 A/G (rs1800682) polymorphisms in Fas as well as single nucleotide polymorphisms INV2nt -124 A/G (rs5030772) and -844 C/T (rs763110) in FasL in a sample of Iranian patients with breast cancer. This case-control study was done on 134 breast cancer patients and 152 normal women. Genomic DNA was extracted from whole blood samples. The polymorphisms were determined by using tetra-ARMS-PCR method. There was no significant difference in the genotype distribution of FAS rs2234767 polymorphism between cases and controls. FAS rs1800682, FASL rs5030772, and FASL rs763110 genotypes showed significant associations with an increasing risk of breast cancer (odds ratio OR = 3.18, P = 0.019; OR = 5.08, P = 0.012; OR = 2.40, P = 0.024, respectively). In conclusion, FAS rs2234767 was not associated with breast cancer risk. Though, FAS rs1800682, FASL rs5030772, and FASL rs763110 polymorphisms were associated with the risk of breast cancer in the examined population.
format article
author Mohammad Hashemi
Aliakbar Fazaeli
Saeid Ghavami
Ebrahim Eskandari-Nasab
Farshid Arbabi
Mohammad Ali Mashhadi
Mohsen Taheri
Wiem Chaabane
Mayur V Jain
Marek J Łos
author_facet Mohammad Hashemi
Aliakbar Fazaeli
Saeid Ghavami
Ebrahim Eskandari-Nasab
Farshid Arbabi
Mohammad Ali Mashhadi
Mohsen Taheri
Wiem Chaabane
Mayur V Jain
Marek J Łos
author_sort Mohammad Hashemi
title Functional polymorphisms of FAS and FASL gene and risk of breast cancer - pilot study of 134 cases.
title_short Functional polymorphisms of FAS and FASL gene and risk of breast cancer - pilot study of 134 cases.
title_full Functional polymorphisms of FAS and FASL gene and risk of breast cancer - pilot study of 134 cases.
title_fullStr Functional polymorphisms of FAS and FASL gene and risk of breast cancer - pilot study of 134 cases.
title_full_unstemmed Functional polymorphisms of FAS and FASL gene and risk of breast cancer - pilot study of 134 cases.
title_sort functional polymorphisms of fas and fasl gene and risk of breast cancer - pilot study of 134 cases.
publisher Public Library of Science (PLoS)
publishDate 2013
url https://doaj.org/article/7e2d543571ef413db0b9f32ac554a79c
work_keys_str_mv AT mohammadhashemi functionalpolymorphismsoffasandfaslgeneandriskofbreastcancerpilotstudyof134cases
AT aliakbarfazaeli functionalpolymorphismsoffasandfaslgeneandriskofbreastcancerpilotstudyof134cases
AT saeidghavami functionalpolymorphismsoffasandfaslgeneandriskofbreastcancerpilotstudyof134cases
AT ebrahimeskandarinasab functionalpolymorphismsoffasandfaslgeneandriskofbreastcancerpilotstudyof134cases
AT farshidarbabi functionalpolymorphismsoffasandfaslgeneandriskofbreastcancerpilotstudyof134cases
AT mohammadalimashhadi functionalpolymorphismsoffasandfaslgeneandriskofbreastcancerpilotstudyof134cases
AT mohsentaheri functionalpolymorphismsoffasandfaslgeneandriskofbreastcancerpilotstudyof134cases
AT wiemchaabane functionalpolymorphismsoffasandfaslgeneandriskofbreastcancerpilotstudyof134cases
AT mayurvjain functionalpolymorphismsoffasandfaslgeneandriskofbreastcancerpilotstudyof134cases
AT marekjłos functionalpolymorphismsoffasandfaslgeneandriskofbreastcancerpilotstudyof134cases
_version_ 1718422611103318016